Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents

被引:22
作者
Brouillard, JE
Terriff, CM
Tofan, A
Garrison, MW
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pharm, Spokane, WA 99204 USA
[2] Washington State Univ, Dept Pharm, Spokane, WA USA
[3] Sacred Heart Med Ctr, Dept Pharm, Spokane, WA USA
[4] Royal Columbian Hosp, Dept Pharm, New Westminster, BC, Canada
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 01期
关键词
bioterrorism agents; antibiotic selection; antibiotic resistance; doxycycline; fluoroquinolones; postexposure prophylaxis;
D O I
10.1592/phco.2006.26.1.3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bacillus anthracis (anthrax), Yersinia pestis (plague), Francisella tularensis (tularemia), Coxiella burnetti (Q fever), and Brucella sp (brucellosis) are all potential bioterrorism agents. Their known virulence, potential lethality, and ability to develop resistance to known antibiotic treatments make these pathogens particularly dangerous. We reviewed the scientific literature by searching MEDLINE databases and published abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the infectious Diseases Society of America from 1989-2005 for studies of each of these biologic agents with the specific aim of examining whether doxycycline or a fluoroquinolone should be stockpiled for mass-scale postexposure prophylaxis. An evidence-based approach was used to determine whether doxycycline or fluoroquinolones were efficacious (both in vitro and in vivo) against these biologic agents and to examine these drugs' respective susceptibility patterns and differences in cost, based on available data. Little published data are available on these pathogens, and much of the data are from studies that used older strains obtained from patient or animal sources in outbreaks decades ago. Doxycycline appears to show comparable minimum inhibitory concentrations to those of the fluoroquinolone class in most clinical and in vitro studies, perhaps with the exception of inhalation plague. Studies also suggest that development of antibiotic resistance is less likely to occur with doxycycline. Doxycycline is several-fold less expensive than most fluoroquinolones and appears to have similar efficacy in most scenarios based on clinical case studies and established Clinical and Laboratory Standards Institute (formerly known as the National Committee for Clinical Laboratory Standards) breakpoints for staphylococci. Therefore, doxycycline should be considered as a first-line antibiotic in the management of bioterrorism agents. Key Words: bioterrorism agents, antibiotic selection, antibiotic resistance, doxycycline, fluoroquinolones, postexposure prophylaxis.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 65 条
[1]   Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis [J].
Agalar, C ;
Usubutun, S ;
Turkyilmaz, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (08) :535-538
[2]   QUINOLONES IN TREATMENT OF HUMAN BRUCELLOSIS - COMPARATIVE TRIAL OF OFLOXACIN-RIFAMPIN VERSUS DOXYCYCLINE-RIFAMPIN [J].
AKOVA, M ;
UZUN, O ;
AKALIN, HE ;
HAYRAN, M ;
UNAL, S ;
GUR, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1831-1834
[3]   Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigs [J].
Altboum, Z ;
Gozes, Y ;
Barnea, A ;
Pass, A ;
White, M ;
Kobiler, D .
INFECTION AND IMMUNITY, 2002, 70 (11) :6231-6241
[4]  
Anonymous, 2001, MMWR Morb Mortal Wkly Rep, V50, P909
[5]  
[Anonymous], 2002, M100S12 NCCLS
[6]  
*ANTHR VACC IMM PR, 2002, ANTHR SPOR PERS LUNG
[7]   Treatment of tularemia with levofloxacin [J].
Aranda, EA .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (03) :167-168
[8]   Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: A prospective, randomized study [J].
Bayindir, Y ;
Sonmez, E ;
Aladag, A ;
Buyukberber, N .
JOURNAL OF CHEMOTHERAPY, 2003, 15 (05) :466-471
[9]   In vitro antimicrobial susceptibility of Brucella species [J].
Baykam, N ;
Esener, H ;
Ergönül, Ö ;
Eren, S ;
Çelikbas, AK ;
Dokuzoguz, B .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (04) :405-407
[10]  
BERTRAND A, 1988, PATHOL BIOL, V36, P493